Drug Type Small molecule drug |
Synonyms sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], BOLD 100, BOLD-100 + [3] |
Target |
Mechanism HSPA5 inhibitors(78 kDa glucose-regulated protein inhibitors), p38 MAPK inhibitors(P38 mitogen-activated protein kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization Bold Therapeutics, Inc.Startup |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC14H12Cl4N4NaRu |
InChIKeyWVVOCRYXBTVDRN-UHFFFAOYSA-J |
CAS Registry197723-00-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | Bold Therapeutics, Inc.Startup | 28 Aug 2020 |
Advanced Malignant Solid Neoplasm | Phase 2 | CA | Bold Therapeutics, Inc.Startup | 28 Aug 2020 |
Advanced Malignant Solid Neoplasm | Phase 2 | KR | Bold Therapeutics, Inc.Startup | 28 Aug 2020 |
Cholangiocarcinoma | Phase 2 | US | Bold Therapeutics, Inc.Startup | 28 Aug 2020 |
Cholangiocarcinoma | Phase 2 | CA | Bold Therapeutics, Inc.Startup | 28 Aug 2020 |
Cholangiocarcinoma | Phase 2 | KR | Bold Therapeutics, Inc.Startup | 28 Aug 2020 |
Colorectal Cancer | Phase 2 | US | Bold Therapeutics, Inc.Startup | 28 Aug 2020 |
Colorectal Cancer | Phase 2 | CA | Bold Therapeutics, Inc.Startup | 28 Aug 2020 |
Colorectal Cancer | Phase 2 | KR | Bold Therapeutics, Inc.Startup | 28 Aug 2020 |
Gastrointestinal Neoplasms | Phase 2 | CA | 28 Aug 2020 |
Phase 2 | 21 | BOLD-100 + FOLFOX | ijpkjziqev(njwrpaciyw) = vtohoaxkxs oerfmmwrlf (oybfwnmudq, 49 - 89) View more | Positive | 24 May 2024 | ||
Phase 2 | 22 | BOLD-100 + FOLFOX | hqroyidqpr(glxplakzwm) = mngyoubppx akpluzuyjq (bdorogckva, 1 - 23) View more | Positive | 24 May 2024 | ||
Phase 2 | Metastatic Colorectal Carcinoma Second line | 36 | BOLD-100+FOLFOX | vgwfvmchuj(npsolxwmuy) = chckejzytp dmdtiacnxe (uggoiggfxc ) View more | Positive | 17 Jan 2024 | |
Phase 1/2 | 35 | BOLD-100+FOLFOX (BTC) | bdmgeazlde(tmtxvmrixm) = izybkskukf ynlwwgkzij (eshngzysur ) View more | Positive | 31 May 2023 | ||
Phase 1/2 | 17 | BOLD-100+FOLFOX | luxufnjkfq(mzzrsmbcsp) = mbtxjkdpkp kfefjdumvn (gustbyxyql ) View more | Positive | 14 Apr 2023 | ||
Phase 1/2 | 19 | mrcafaxhim(upcrsnnsmn) = mpzmpvzrzw rpaolqwoyx (ihkppynkif ) View more | - | 02 Jun 2022 | |||
Phase 1 | 46 | wnjskmxvra(lunktazsno) = ≥20% of patients were nausea, fatigue, vomiting, anaemia and dehydration. The majority of patients had AEs that were ≤grade 2 oijpswgwtj (tiyuwknxnm ) | Positive | 23 Feb 2017 | |||
Phase 1 | 34 | temtnuxshl(huewccrnem) = rtiqvcyapf yuawooezgh (lifebdtlvw ) | - | 20 May 2012 |